NCT06920134招募中不适用
Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Support Hemodynamic Management in People With Typical and Atypical Parkinson's Disease
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 5
- 试验地点
- 2
- 主要终点
- Occurrence of (serious) adverse device effects of the ARC-IM Therapy from baseline up to the end of the study.
研究概览
简要总结
The PD-HemON study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support hemodynamic management in people with typical and atypical Parkinson's Disease, who suffer from orthostatic hypotension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •> 18 years old
- •Typical or Atypical PD (including but not limited to Multiple System Atrophy, Pure Autonomic Failure, Progressive Supranuclear Palsy)
- •Confirmed orthostatic hypotension with a test for verticalization
- •Confirmed symptomatic orthostatic hypotension that makes daily activities particularly challenging as determined by the study clinicians
- •Must provide and sign the Informed Consent before any study-related procedures
- •Stable medical, physical, and psychological conditions given participant indication as considered by Investigators;
- •Able to understand and interact with the study team in French or English
- •Agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments
排除标准
- •Diseases and conditions that would increase the morbidity and mortality of the implantation surgery
- •The inability to withhold antiplatelet/anticoagulation agents perioperatively
- •History of myocardial infarction or cerebrovascular events within the past 6 months
- •Unstable or significant medical condition that is likely to interfere with study procedures or likely to confound study endpoint evaluations as determined by the Investigator
- •History or presence of major psychiatric disorders or major neurocognitive disorders as considered by the Investigators in accordance with the treating physician and treating neurologist
- •Major changes in PD treatment planned until the end of the main study phase (such as DBS or dopamine-pump implantation)
- •Inability to follow study procedures.
- •Spinal anatomical abnormalities precluding surgery
- •Presence of any indications requiring frequent MRIs.
- •Current pregnancy or current breastfeeding
- •Lack of effective or acceptable contraception for women of childbearing capacity
- •Intention to become pregnant during the study
- •Unable or unwilling to effectively use the study system or related devices by the participant or caretaker, as determined by the investigator
- •Participation in another interventional study that might confound study endpoint evaluations
- •Enrolment of the investigator, his/her family members, employees, and other dependent persons
研究组 & 干预措施
All participants
Experimental
All participants will be provided with the ARC-IM Investigational System (implantable and non-implan
干预措施: ARC-IM Investigational System (Device)
结局指标
主要结局
Occurrence of (serious) adverse device effects of the ARC-IM Therapy from baseline up to the end of the study.
时间窗: Throughout the study (up to 5 years)
Evaluate the safety of ARC-IM Therapy in supporting hemodynamic management in participants with atypical or typical Parkinson's Disease and orthostatic hypotension
次要结局
- 10-minute, orthostatic head-up tilt test with and without the ARC-IM Therapy at 1 month after intervention(At the end of, 6 months after and 1 year after configuration of the therapy,)
- Severity of symptoms measured by The Orthostatic Hypotension Questionnaire.(At the end of, 6 months after and 1 year after configuration of the therapy)
- Time Up and Go Test (TUG)(At the end of, 6 months after and 1 year after configuration of the therapy)
- 2 Minute Walk Test(At the end of, 6 months after and 1 year after configuration of the therapy)
- Berg Balance Test(At the end of, 6 months after and 1 year after configuration of the therapy)
- Quebec User Evaluation of Satisfaction with technology (QUEST 2.0)(At 6 months and 1 year after configuration of the therapy)
- System Usability Scale (SUS)(At 6 months and 1 year after configuration of the therapy)
- Additional user feedback of ARC-IM System(At 6 months and 1 year after configuration of the therapy)
研究者
Jocelyne Bloch
Professor
Centre Hospitalier Universitaire Vaudois
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Study on Preliminary Safety and Efficacy of the ARC-IM Therapy to Alleviate Locomotor Deficits in People With Parkinson's DiseaseParkinson DiseaseNCT06295614Ecole Polytechnique Fédérale de Lausanne6
招募中
不适用
Study on Preliminary Safety and Efficacy of the ARC Therapy Using the ARC-IM Lumbar System to Support Mobility in People With Chronic Spinal Cord Injury (BoxSwitch)Spinal Cord InjuriesNCT05942339Ecole Polytechnique Fédérale de Lausanne8
已完成
1 期
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastNCT03088527Stemline Therapeutics, Inc.20
尚未招募
1 期
Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate CancerProstate CancerNCT06062355Jiangsu HengRui Medicine Co., Ltd.9
招募中
不适用
ARC Therapy to Restore Hemodynamic Stability and Trunk Control in People With Spinal Cord InjurySpinal Cord InjuryOrthostatic HypotensionNCT05941819ONWARD Medical, Inc.16